Information about Geographic Areas

9 Months Ended

Sep. 30, 2017

The Company operates as a single reportable segment and enables customers to perform both research and clinical testing on its nCounter Analysis Systems. The Company has one sales force that sells these systems to both research and clinical testing labs, and its nCounter Elements reagents can be used for both research and diagnostic testing. In addition, the Company’s Prosigna Breast Cancer Assay is marketed to clinical laboratories. The Company has also entered into collaboration agreements with Celgene, Merck, Lam, and previously Medivation and Astellas.

The following table of total revenue is based on the geographic location of the Company’s customers, distributors and collaborators. For sales to distributors, their geographic location may be different from the geographic locations of the ultimate end user. Americas consists of the United States, Canada, Mexico and South America; and Asia Pacific includes Japan, China, South Korea, Singapore, Malaysia, India and Australia. Revenue by geography was as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Americas	$	20,060	$	16,784	$	59,612	$	43,188
Europe & Middle East	4,911		4,934		14,564		12,667
Asia Pacific	2,045		2,215		5,496		5,402
Total revenue	$	27,016	$	23,933	$	79,672	$	61,257

Total revenue in the United States was $19.7 million and $16.2 million for the three months ended September 30, 2017 and 2016, respectively, and $58.3 million and $41.5 million for the nine months ended September 30, 2017 and 2016, respectively. The Company’s assets are primarily located in the United States and not allocated to any specific geographic region. Substantially all of the Company’s long-lived assets are located in the United States.